Search Clinical Trials in the EU

Duration

6-10 visits

Phase

Intake methods

Benefits

Drugs

Locations

Clinical Specialty

181-200 of 604 trials

Severe Systemic Lupus Erythematosus: Belimumab and Rituximab Study

We are investigating whether combining belimumab with rituximab can improve treatment outcomes for people with severe systemic lupus erythematosus. This study will compare this combination to standard treatments to see if it better reduces harmful autoantibodies and improves overall health.

Systemic Lupus Erythematosus>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visits No Placebo Standard Medicines Cost ReimbursementInternal MedicineRheumatology

Multiple Myeloma: Elranatamab vs. Standard Treatments

We are studying a new treatment called elranatamab for people with relapsed refractory multiple myeloma. The goal is to see how well it works compared to current therapies and to assess its safety and impact on quality of life.

Relapsed/Refractory Multiple MyelomaConfirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Investigational Medicines Cost Reimbursement Partially RemoteHematologyOncology

Methylphenidate for Cancer-Related Fatigue in Young Brain Tumor Survivors

We are studying whether methylphenidate can help reduce fatigue in patients who were treated for brain tumors during childhood or adolescence. Additionally, we will look at its effects on sleep, cognitive function, and quality of life.

Cancer-related Fatigue after Pediatric Brain Tumor Treatment3-6 monthsConfirmation phase (III)6-10 visits Standard Medicines Cost ReimbursementOncologyPediatrics

Pompe Disease: Enzyme Replacement Therapy Study

We are examining how a new enzyme replacement therapy affects muscle glycogen in people with Pompe disease who have not yet received treatment. This research may help improve future therapies for this condition.

Pompe's Disease>2 yearsMonitoring phase (IV)6-10 visits No Placebo Standard Medicines Cost ReimbursementEndocrinologyHematologyNeurology

Ovarian Cancer: Sacituzumab Tirumotecan Study

We are testing a new treatment for people with recurrent ovarian cancer to see if it works better than standard care. This study looks at safety, tolerability, and how it affects patients' quality of life.

Recurrent Ovarian CancerConfirmation phase (III)6-10 visits Investigational Medicines Cost ReimbursementOncology

Polymyalgia Rheumatica: Secukinumab Safety Study

We are evaluating the long-term safety of secukinumab for individuals with polymyalgia rheumatica. This study will help us understand any potential side effects associated with this treatment.

Polymyalgia Rheumatica>2 yearsConfirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Standard Medicines Cost ReimbursementInternal MedicineRheumatology

Advanced Biliary Cancer: Personalized Targeted Therapy

We are studying whether a new personalized treatment can help patients with advanced biliary cancer live longer without disease progression compared to standard care. This trial also examines the quality of life and safety of the new therapies.

Advanced Biliary Cancer>2 yearsConfirmation phase (III)6-10 visits No Placebo Investigational MedicinesInternal MedicineOncology

COVID-19 Treatment: Anti-Coronavirus Immunoglobulin Study

We are testing a new immunoglobulin treatment for adults recently diagnosed with COVID-19 to see if it improves health outcomes compared to a placebo. This study aims to understand its safety and effectiveness alongside standard care.

COVID-19≤3 monthsConfirmation phase (III)6-10 visits Investigational Medicines Partially RemoteInfectious DiseasesInternal Medicine

Bipolar Depression: Esketamine Nasal Spray

We are studying the safety and effectiveness of esketamine nasal spray for people with treatment-resistant bipolar depression. This trial aims to gather important information that could lead to future studies.

Bipolar Disorder - Depressive Episode≤3 monthsEfficacy phase (II)6-10 visits No Placebo Investigational MedicinesPsychiatry

Methylprednisolone for Infants with Neuroendocrine Cells Hyperplasia

We are studying whether methylprednisolone pulses can reduce the need for oxygen therapy in infants with NEHI. The trial also examines the treatment's effects on respiratory health and quality of life.

Neuroendocrine Cell Hyperplasia of Infancy>2 yearsEfficacy phase (II)6-10 visits No Placebo Standard Medicines Partially RemoteInternal MedicinePulmonology

Crohn’s Disease: MORF-057 Treatment Study

We are testing a new medication, MORF-057, for adults with moderately to severely active Crohn’s disease. The study aims to see if it improves symptoms and endoscopic results compared to a placebo.

Crohn's Disease1-2 yearsEfficacy phase (II)6-10 visits Post-Trial Drug Access Investigational MedicinesGastroenterologyInternal Medicine

Antiplatelet Therapy Duration After TAVI

We are studying whether a shorter 3-month antiplatelet therapy is as effective as the standard 12-month therapy after TAVI. The goal is to see if it reduces complications and bleeding risks.

Aortic Stenosis>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visits No Placebo Standard Medicines Partially RemoteCardiologyInternal Medicine

Tolvaptan for Children with Autosomal Recessive Polycystic Kidney Disease

We are studying the safety and effects of tolvaptan in infants and children with ARPKD. The trial aims to see if it helps reduce the need for kidney treatments.

Autosomal Recessive Polycystic Kidney DiseaseConfirmation phase (III)6-10 visits Post-Trial Drug Access No Placebo Standard Medicines Cost Reimbursement Partially RemoteNephrologyPediatrics

Chronic Inflammatory Bowel Disease: Intravenous Lidocaine Study

We are investigating whether intravenous lidocaine can reduce abdominal pain in patients with chronic inflammatory bowel disease. Additionally, we will study how this treatment affects brain activity compared to healthy volunteers.

Inflammatory Bowel Disease3-6 monthsEfficacy phase (II)6-10 visits No Placebo Standard MedicinesGastroenterologyInternal Medicine

MDMA-Assisted Therapy for Treatment-Resistant PTSD

We are studying whether MDMA-assisted therapy can improve symptoms of PTSD in individuals who have not responded to other treatments. This trial also looks at how well this therapy works in a hospital setting.

Posttraumatic Stress Disorder6-12 monthsEfficacy phase (II)6-10 visits No Placebo Investigational Medicines Partially RemotePsychiatry

Renal Lifecycle Trial: Dapagliflozin for Severe Chronic Kidney Disease

We are studying whether dapagliflozin can improve kidney and heart health in patients with severe chronic kidney disease. This includes those on dialysis and kidney transplant recipients.

Healthy Participants>2 yearsConfirmation phase (III)6-10 visits Investigational MedicinesCardiologyNephrology

Progressive Pulmonary Fibrosis: Inhaled Pirfenidone Study

We are testing an inhaled medication to see if it helps improve lung function and quality of life for people with Progressive Pulmonary Fibrosis. This study compares the medication to a placebo to assess its effects over time.

Progressive Pulmonary Fibrosis1-2 yearsEfficacy phase (II)6-10 visits Post-Trial Drug Access Standard MedicinesPulmonology

Scleroderma: Stem Cell Injections for Digital Ulcers

We are studying if injections of cultured fat cells can help heal stubborn digital ulcers in patients with scleroderma. This trial compares the treatment to a placebo to evaluate its effectiveness and safety.

Systemic Sclerosis>2 yearsEfficacy phase (II)6-10 visits Investigational Medicines Cost ReimbursementInternal MedicineRheumatology

Neutropenia: Mavorixafor Study

We are investigating a new medication, mavorixafor, for people with neutropenia who have frequent infections. The study will assess how well it works and its safety compared to a placebo.

Neutropenia1-2 yearsConfirmation phase (III)6-10 visits Post-Trial Drug Access Investigational Medicines Cost Reimbursement Partially RemoteHematologyInfectious DiseasesInternal Medicine

Preventing Blood Clots: REGN9933 and REGN7508 Study

We are studying two new medications to see if they can help prevent blood clots in adults with a peripherally inserted central catheter. The trial will also assess how safe these treatments are.

Venous Thromboembolism3-6 monthsEfficacy phase (II)6-10 visits Investigational Medicines Cost Reimbursement Partially RemoteCardiologyHematology

Search Clinical Trials in the European Union